江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2025-054 江苏森萱医药股份有限公司独立董事工作细则 江苏森萱医药股份有限公司于 2025 年 8 月 28 日召开第四届董事会第十次会 议，审议通过了《关于制定及修订公司部分内部管理制度的议案》之子议案 5.05： 修订《独立董事工作细则》；议案表决结果：同意 7 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 第一章 总则 第一条 为进一步完善江苏森萱医药股份有限公司（以下简称"公司"）治 理结构，充分发挥公司独立董事作用，保护中小股东及利益相关者的利益，促进 公司的规范运作，根据《中华人民共和国公司法》（以下简称《公司法》）、《中 华人民共和国证券法》《北京证券交易所股票上市规则》（以下简称《上市规则》）、 《北京证券交易所上市公司持续监管指引第 1 号——独立董事》（以下简称《监 管指引第 1 号》）、《上市公司独立董事管理办法》等相关法律、行政法规、规 范性文件以及《江苏森萱医药股份有限公司章程》（以下简称《公司章程》）等有 关规定，制定本工作细则。 第二条 独立董事是 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2025-064 江苏森萱医药股份有限公司防止大股东及关联方占用上市 公司资金管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 江苏森萱医药股份有限公司于 2025 年 8 月 28 日召开第四届董事会第十次会 议，审议通过了《关于制定及修订公司部分内部管理制度的议案》之子议案 5.15： 修订《防止大股东及关联方占用上市公司资金管理制度》；议案表决结果：同意 7 票，反对 0 票，弃权 0 票。 本议案尚需提交股东会审议。 二、 分章节列示制度主要内容： 第一章 总则 第一条 为了进一步加强和规范江苏森萱医药股份有限公司（包括控股子公 司，以下简称"公司"）的资金管理，防止和杜绝大股东及关联方占用公司资金 行为的发生，保护公司、股东和其他利益相关人的合法权益，根据《中华人民共 和国公司法》、《中华人民共和国证券法》、《北京证券交易所股票上市规则》等有 关法律、行政法规、规范性文件及《江苏森萱医 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2025-073 江苏森萱医药股份有限公司信息披露管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 审议及表决情况 江苏森萱医药股份有限公司于 2025 年 8 月 28 日召开第四届董事会第十次会 议，审议通过了《关于制定及修订公司部分内部管理制度的议案》之子议案 5.24： 修订《信息披露管理制度》；议案表决结果：同意 7 票，反对 0 票，弃权 0 票。 本议案无需提交股东会审议。 二、 分章节列示制度主要内容： 第一章 总 则 第一条 为规范江苏森萱医药股份有限公司(以下简称 "公司")信息披露 行为，加强信息披露事务管理，确保公司信息披露的真实、准确、完整与及时， 切实保护公司、股东、债权人及其他利益相关人的合法权益，依据《中华人民共 和国公司法》(以下简称《公司法》)、《中华人民共和国证券法》(以下简称《证 券法》)、《北京证券交易所股票上市规则》（以下简称《上市规则》）、《上市公司 信息披露管理办 ...

Group 1 - The establishment of the Beijing Stock Exchange (BSE) is a significant milestone in the high-quality development of China's multi-level capital market, aimed at serving innovative small and medium-sized enterprises (SMEs) [2][3] - As of March 9, 2022, the BSE has 87 listed companies with a total market capitalization exceeding 200 billion yuan, and over 90% of the companies reported positive net profits for 2021 [2] - The BSE's market structure is designed to support innovative SMEs, with 87% of listed companies in strategic emerging industries, advanced manufacturing, and modern services [3] Group 2 - The BSE operates under a registration-based system, enhancing transparency and efficiency in the listing process, which is expected to broaden the benefits of capital market reforms [3][4] - The BSE has established a pyramid-shaped market structure, with all listed companies originating from the innovative tier of the New Third Board, enhancing market connectivity [4] - The BSE is designed specifically for innovative SMEs, providing them with new financing channels and opportunities to enter the capital market earlier [5]

江苏森萱医药股份有限公司 一、原料药基本情况 证券代码：830946 证券简称：森萱医药 公告编号：2025-041 江苏森萱医药股份有限公司 关于全资子公司获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 近日，江苏森萱医药股份有限公司（以下简称"公司"）全资子公司精华 制药集团南通有限公司（以下简称"南通公司"）获得国家药品监督管理局核 准签发的利托那韦《化学原料药上市申请批准通知书》，现就相关情况公告如 下： 登记号：Y20230001302 受理号：CYHS2460104 化学原料药名称：通用名称：利托那韦 英文名/拉丁名：Ritonavir 化学原料药注册标准编号：YBY67042025 有效期：18 个月 包装规格：1kg/袋；2kg/袋；5kg/袋；10kg/袋； 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 生产企业：精华制药集团南通有限公司 ...

Core Viewpoint - Jiangsu Senxuan Pharmaceutical Co., Ltd. announced that its subsidiary, Ningxia Senxuan Pharmaceutical Co., Ltd., and its safety and environmental protection department head, Huang Xionghu, are being prosecuted for environmental pollution, with a recommended fine of 400,000 to 600,000 yuan [1][4]. Group 1: Legal Proceedings - Ningxia Senxuan is a subsidiary of Jiangsu Senxuan, primarily engaged in the production of pesticide intermediates [3][8]. - The prosecution stems from an incident on February 20, 2024, where due to a frozen wastewater discharge pipeline, Huang Xionghu arranged for untreated wastewater to be illegally disposed of, resulting in the dumping of approximately 150 tons of toxic waste [3][8]. - The public prosecutor claims that this act caused property damage amounting to 857,897.97 yuan [3][8]. Group 2: Company Background and Operations - Ningxia Senxuan was established in November 2018 with a registered capital of 70 million yuan and is a subsidiary of the state-owned enterprise Jinghua Pharmaceutical Group [4]. - The company focuses on the research, production, and sales of pharmaceuticals and intermediates, with Lin Guoping as the legal representative and Zhu Shizhang as the chairman [4]. Group 3: Impact on Company Operations - Following the incident, the company has taken corrective actions, including ceasing operations for rectification, which was later approved by the local environmental authority for resumption of production [11]. - The company emphasizes its commitment to compliance and environmental protection, stating it will manage the situation proactively and maintain transparency regarding the legal proceedings [11]. Group 4: Financial Implications - As of the announcement date, the case has not yet gone to trial, and the exact fine amount remains uncertain [12]. - The company plans to handle the financial implications according to accounting standards and will disclose relevant information as required [12].

江苏森萱医药股份有限公司 （一）（原告/上诉人）基本信息： 姓名或名称：银川铁路运输检察院 法定代表人/法定代理人/其他负责人：- 诉讼代理人及所属律所：周晓婷、暂无 （二）（被告/被上诉人）基本信息： 姓名或名称：宁夏森萱药业有限公司（被告一） 法定代表人/法定代理人/其他负责人：林国平 诉讼代理人及所属律所：薛忠才、江苏崇诚律师事务所 江苏森萱医药股份有限公司 被告单位宁夏森萱药业有限公司（以下简称"宁夏森萱"）系江苏森萱医 药股份有限公司（以下简称"森萱医药"、"公司"）控股子公司，宁夏森萱生产 农药医药中间体氟乙酸甲酯、氟乙酸乙酯、氯乙酸甲酯、氯乙酸乙酯。宁夏森 萱系危险废物产废单位。被告人黄雄虎系宁夏森萱安环部部长，非宁夏森萱和 森萱医药董事、高管。2024 年 2 月 20 日左右，因宁夏森萱所在的园区污水排 放管道冻裂，无法处置废水，负责安全环保黄雄虎联系中间人贺某某和园区环 境监管部门李某某，以 320 元每吨价格，将宁夏森萱废水处理站暂存池中未经 处理的废水交由贺某某拉运到外地污水处理厂处置，贺某某组织拉运 5 车约 150 吨废水直接倾倒在原石炭井一废弃学校院内，造成了环境污染。 （四）诉 ...

江苏森萱医药股份有限公司 证券代码：830946 证券简称：森萱医药 公告编号：2025-039 江苏森萱医药股份有限公司 关于完成注册地址变更并取得营业执照的公告 江苏森萱医药股份有限公司（以下简称"公司"）根据自身发展现状及未来 战略规划，对公司注册地址进行变更，具体变更情况如下： | 变更项目 | 变更前 | 变更后 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 注册地址 | 泰兴市虹桥镇中丹路西侧 | 南通市如东县洋口镇双墩路 | | | | 2 号 | | | | 听海轩 4 | 幢 | 7 | 层 | | 除注册地址发生变更外，其他工商信息未发生变更；公司办公地址未发生变 化，仍为江苏省南通市崇川区青年中路 198 号国城生活广场办公楼 A 幢 21 楼。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 一、基本情况 二、审议情况 本次注册地址的变更事项已经公司第四届董事会第八次会议及 2024 年年度 股东会审议通过。 三、工商登记情况 近日，公 ...

Investment Rating - The investment rating for the company is upgraded to "Outperform" [2] Core Views - The company reported a revenue of 537 million yuan in 2024, a year-on-year decline of 8.89%, with a net profit attributable to the parent company of 124 million yuan, down 8.00% year-on-year [2] - The company has increased its patent count to 192, with 42 invention patents, indicating a strong focus on research and development [3] - The company is implementing a strategy to refine its raw material drug structure, specialize in intermediates, and expand into new materials and innovative drugs [4] Financial Summary - The company achieved a revenue of 590 million yuan in 2023, with a projected revenue of 706 million yuan by 2027, reflecting a compound annual growth rate [5] - The gross profit margin is expected to remain stable around 43.4% to 43.9% from 2025 to 2027 [5] - The earnings per share (EPS) is projected to increase from 0.30 yuan in 2025 to 0.41 yuan in 2027 [5] Revenue and Profit Forecast - The forecast for net profit attributable to the parent company is adjusted to 130 million yuan for 2025, 153 million yuan for 2026, and 174 million yuan for 2027 [2][5] - The company anticipates a slight revenue increase in 2025, with a projected revenue of 544 million yuan, followed by a more significant growth in subsequent years [5] Market Position and Product Development - The company has successfully registered new raw materials in the European and American markets, which is expected to contribute to future revenue growth [3] - The production of the new raw material drug projects is underway, with a focus on expanding the product line [3]

Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1]. Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12]. - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15]. - The innovative drug segment is experiencing a pullback due to U.S. President Trump's announcement regarding drug price reductions, but the report suggests that the actual implementation of such policies will be challenging and will not significantly impact Chinese innovative drug companies' international expansion [3][20]. Summary by Sections 1. Market Review - The pharmaceutical sector's performance from May 12 to May 16, 2025, showed a 1.27% increase, outperforming the CSI 300 index by 0.15 percentage points [10]. - Year-to-date, the sector has increased by 2.48%, surpassing the CSI 300 index by 3.64 percentage points [12]. 2. Key Events - On May 12, 2025, President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially lowering prices by 30% to 80% [19]. 3. Industry Perspective - The innovative drug sector is expected to continue as a key investment theme for 2025, with a focus on international expansion and emerging markets, particularly in companies like Kexing Pharmaceutical [4][21]. - The report highlights that the ongoing collection and procurement policies in various pharmaceutical fields are accelerating, with potential growth in segments like insulin and orthopedics [4][21].